Janssen v. Hikma — S-Ketamine Patent Infringement Action Consolidated (134 Days)
Janssen Pharmaceuticals and Janssen Pharmaceutica N.V. filed suit against Hikma Pharmaceuticals USA, West-Ward Columbus, and Hikma Pharmaceuticals PLC in the District of New Jersey, asserting four patents covering S-ketamine hydrochloride compositions and methods for treating depression. The case was consolidated into lead action 23-2939 after 134 days.
Four S-Ketamine Patents, Three Hikma Entities, One Consolidated Docket
On 30 May 2023, Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica N.V. filed this infringement action in the District of New Jersey against Hikma Pharmaceuticals USA, Inc., West-Ward Columbus, Inc., and Hikma Pharmaceuticals PLC. The complaint asserted four United States patents — US10869844B2, US11173134B2, US11446260B2, and US11311500B2 — covering pharmaceutical compositions of S-ketamine hydrochloride and methods for the treatment of depression.
The case did not proceed to a merits ruling in this docket. On 11 October 2023, the court entered a Stipulation and Order consolidating Civil Action Nos. 23-2942 and 23-2943 with Civil Action No. 23-2939, designating 23-2939 as the lead action. All papers are to be maintained in the lead action going forward. The recorded basis of termination is 'Case Consolidated.'
The consolidation occurred 134 days after filing, suggesting the related actions — which appear to involve the same or overlapping parties and patents — were identified and joined at an early procedural stage. The substantive merits of the infringement claims, and any defences Hikma may raise, will be adjudicated in lead action 23-2939. The specific terms of any underlying agreements or litigation strategy are not disclosed in the available record of this docket.
See Complete Case & Patent Analysis →Filing to Case Consolidated in 134 days
134 days from filing to consolidation order — a swift procedural resolution before substantive merits proceedings
US10869844B2 — S-Ketamine Hydrochloride Compositions and Depression Treatment Methods
Any pharmaceutical company, CDMO, or drug delivery innovator developing S-ketamine hydrochloride products, esketamine formulations, or novel methods of treating treatment-resistant depression should assess exposure against all four patents asserted in this case. The involvement of three Hikma entities signals that even vertically integrated generic groups face multi-patent enforcement risk in this space. FTO analysis is advisable before ANDA filing, NDA submission, or commercial launch.
Official order — verbatim text
The consolidation order is purely procedural — it transfers all active litigation to lead action 23-2939 and makes no finding on infringement, validity, or any other substantive issue. Neither party's legal position on the merits is affected by the consolidation itself.
Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Janssen Pharmaceuticals, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Janssen Pharmaceutica, N.V. | Company | Search in Eureka ↗ |
| Defendant | Hikma Pharmaceuticals USA, Inc. | Company | /Search in Eureka ↗ |
| Co-Defendant | West-Ward Columbus, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Hikma Pharmaceuticals, PLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Keith J. Miller | Attorney | Counsel for Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Michael James Gesualdo | Attorney | Counsel for Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Zhiqiang Liu | Attorney | Counsel for Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Patterson Belknap Webb & Tyler | Law Firm | Representing Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Robinson Miller LLC | Law Firm | Representing Janssen Pharmaceuticals, Inc.Search in Eureka ↗ |
| Defendant counsel | James S. Richter | Attorney | Counsel for Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Defendant law firm | MIDLIGE RICHTER LLC | Law Firm | Representing Hikma Pharmaceuticals USA, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
R&D signals in the S-ketamine and antidepressant formulation space
Forward-looking patent and innovation intelligence derived from Janssen's S-ketamine enforcement posture and Hikma's generic pharmaceutical pipeline.
Janssen's S-ketamine filing activity signals ongoing prosecution
Janssen has filed across multiple application waves (US16/727594 through US17/345395), suggesting active continuation prosecution in the esketamine space. Monitoring new publications from Janssen Pharmaceutica N.V. and related J&J entities for continuation claims covering dosing regimens, devices, or patient-selection methods is a key intelligence priority.
Active prosecution watchEsketamine patent filings are expanding beyond intranasal delivery
The S-ketamine IP landscape is broadening from intranasal formulations into IV dosing, long-acting injectables, and digital therapeutics combinations for treatment-resistant depression. Companies filing in adjacent delivery mechanisms or companion diagnostic spaces should map claim overlap with the four Janssen patents before advancing to IND stage.
Landscape broadeningHikma's generic CNS pipeline — patent challenge exposure
Hikma's involvement across three legal entities (USA, West-Ward Columbus, PLC) in this and parallel actions suggests a coordinated generic CNS strategy. Tracking Hikma's own patent filings in the ketamine and anaesthetic space may reveal design-around approaches or formulation alternatives they are pursuing outside the Janssen claim scope.
Generic design-around signalsAdjacent claim space: ketamine metabolites and combination therapies
The asserted patents focus on S-ketamine hydrochloride compositions and depression treatment methods. Adjacent white space may exist around active metabolites (e.g. hydroxynorketamine), novel combination regimens with antidepressants, or non-hydrochloride salt forms — areas less densely claimed in the current Janssen portfolio and potentially open to independent patent filings.
White space: metabolites & combosSimilar S-Ketamine and Hatch-Waxman Patent Cases in D.N.J.
Explore related ANDA patent infringement actions involving S-ketamine, esketamine, and antidepressant formulation patents litigated in the District of New Jersey.
What this consolidation signals for the S-ketamine IP landscape
Multiple parallel Hikma actions merged into one lead docket — a pattern that often signals coordinated ANDA-driven patent challenges across a branded drug portfolio.
Consolidation concentrates risk: watch lead action 23-2939 closely
With three related actions merged, all substantive rulings on validity, infringement, and any 30-month stay under Hatch-Waxman will flow from lead action 23-2939. Patent practitioners and product teams monitoring Hikma's generic S-ketamine programme should redirect docket surveillance to that case number immediately.
Four-patent assertion signals a layered Hatch-Waxman defence strategy
Asserting four patents across compositions and methods of treatment is consistent with a multi-layered Hatch-Waxman enforcement posture designed to extend the litigation lifecycle. Competitors evaluating freedom to operate for intranasal or IV ketamine-based depression therapies should map all four patent families before filing any ANDA or NDA.
Janssen v Hikma — key questions answered
Case 1:23-cv-02942 was a patent infringement action filed by Janssen Pharmaceuticals and Janssen Pharmaceutica N.V. against Hikma Pharmaceuticals USA, West-Ward Columbus, and Hikma Pharmaceuticals PLC. The case was closed after 134 days when the court entered a Stipulation and Order consolidating it with related cases 23-2942 and 23-2943 into lead action 23-2939. No merits ruling was issued in this docket.
Janssen asserted four patents: US10869844B2, US11173134B2, US11446260B2, and US11311500B2. These patents cover pharmaceutical compositions of S-ketamine hydrochloride and methods for the treatment of depression, including treatment-resistant depression.
Consolidation means this action (23-2942) and related case 23-2943 were merged into lead action 23-2939. All future filings, hearings, and substantive rulings on infringement and validity will be handled under the lead docket. The recorded basis of termination for 23-2942 is 'Case Consolidated' — no merits determination was made here.
West-Ward Columbus, Inc. is a Hikma subsidiary. Its inclusion as a co-defendant, alongside Hikma USA and Hikma PLC, is consistent with naming all entities within a corporate group that may be involved in manufacturing, distributing, or commercialising the allegedly infringing product. The specific basis for its inclusion is not elaborated in the available record of this docket.
The active proceedings are being conducted under lead action Civil Action No. 23-2939 in the District of New Jersey. This docket (1:23-cv-02942) was closed upon consolidation on 11 October 2023. Monitoring lead action 23-2939 will provide the current status of all merits proceedings, including any rulings on infringement, validity, or 30-month stay under Hatch-Waxman.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.